Safety evaluation of allogeneic umbilical cord blood mononuclear cell therapy for degenerative conditions

Abstract

The current hematology-based paradigm of need for matching and immune suppression needs to be revisited when cord blood is used for non-hematopoietic regenerative purposes in immune competent recipients.